Ocugen, Inc. Receives Orphan Designation For OCU100 To Treat Retinitis Pigmentosa
6/5/2014 9:48:17 AM
AURORA, Colo.--(BUSINESS WIRE)--Ocugen, Inc. and the University of Colorado today announced exclusive license agreements that allow for Ocugen to continue developing two drug candidates for the treatment for ophthalmology indications, and that one of the assets, OCU100, recombinant lens epithelium derived growth factor 1-326 (LEDGF1-326), received orphan-drug status from the U.S. Food and Drug Administration for treatment of retinitis pigmentosa (RP), a rare eye disease.
Help employers find you! Check out all the jobs and post your resume.
comments powered by